Clinical Trial Update: Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) [Phase 3]

View source ↗

Summary

Phase 3 NIAGARA-2 trial evaluates perioperative durvalumab with neoadjuvant ddMVAC or gemcitabine/cisplatin in muscle-invasive bladder cancer. The study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Doxorubicin (doxorubicin)
• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)
• METHOTREXATE (METHOTREXATE)
• Vinblastine (vinblastine)

Snippet

Sponsor: AstraZeneca | Conditions: Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors | Phase 3 | Status: RECRUITING